收费全文 | 200069篇 |
免费 | 16971篇 |
国内免费 | 9124篇 |
耳鼻咽喉 | 2111篇 |
儿科学 | 2468篇 |
妇产科学 | 2457篇 |
基础医学 | 31223篇 |
口腔科学 | 3866篇 |
临床医学 | 22245篇 |
内科学 | 30614篇 |
皮肤病学 | 3433篇 |
神经病学 | 11032篇 |
特种医学 | 7883篇 |
外国民族医学 | 65篇 |
外科学 | 21222篇 |
综合类 | 23643篇 |
现状与发展 | 30篇 |
一般理论 | 29篇 |
预防医学 | 12843篇 |
眼科学 | 4689篇 |
药学 | 21594篇 |
121篇 | |
中国医学 | 8489篇 |
肿瘤学 | 16107篇 |
2024年 | 601篇 |
2023年 | 2652篇 |
2022年 | 7053篇 |
2021年 | 9316篇 |
2020年 | 6291篇 |
2019年 | 6031篇 |
2018年 | 6624篇 |
2017年 | 5816篇 |
2016年 | 6126篇 |
2015年 | 8898篇 |
2014年 | 10876篇 |
2013年 | 11053篇 |
2012年 | 15950篇 |
2011年 | 16116篇 |
2010年 | 10753篇 |
2009年 | 8776篇 |
2008年 | 11134篇 |
2007年 | 10801篇 |
2006年 | 9672篇 |
2005年 | 8727篇 |
2004年 | 7001篇 |
2003年 | 6554篇 |
2002年 | 5566篇 |
2001年 | 4775篇 |
2000年 | 4204篇 |
1999年 | 3525篇 |
1998年 | 2024篇 |
1997年 | 2038篇 |
1996年 | 1460篇 |
1995年 | 1371篇 |
1994年 | 1234篇 |
1993年 | 897篇 |
1992年 | 1303篇 |
1991年 | 1207篇 |
1990年 | 1065篇 |
1989年 | 989篇 |
1988年 | 896篇 |
1987年 | 810篇 |
1986年 | 708篇 |
1985年 | 591篇 |
1984年 | 487篇 |
1983年 | 413篇 |
1982年 | 324篇 |
1981年 | 287篇 |
1980年 | 238篇 |
1979年 | 283篇 |
1978年 | 260篇 |
1977年 | 250篇 |
1976年 | 236篇 |
1974年 | 218篇 |
2. Firstly, cell viability and biochemical indicators were determined and the cell morphology was observed to confirm the cell injury and develop a cell hepatotoxicity model. Then, with the help of cell metabolomics based on UPLC-MS, the Genkwa Flos group samples were completely separated from the blank group samples in the score plots and seven upregulated as well as two down-regulated putative biomarkers in the loading plot were identified and confirmed. Besides, two signal molecules and four enzymes involved in biosynthesis pathway of lysophosphatidylcholine and the sphingosine kinase/sphingosine-1-phosphate pathway were determined to investigate the relationship between Genkwa Flos hepatotoxicity and these two classic pathways. Finally, the metabolic pathways related to specific biomarkers and two classic metabolic pathways were analyzed to explain the possible mechanism of Genkwa Flos hepatotoxicity.
3. Based on the results, lipid peroxidation and oxidative stress, phospholipase A2/lysophosphatidylcholine pathway, the disturbance of sphingosine-1-phosphate metabolic profile centered on sphingosine kinase/sphingosine-1-phosphate pathway and fatty acid metabolism might be critical participators in the progression of liver injury induced by Genkwa Flos. 相似文献
Objective
The advantage of arteriovenous fistulas (AVFs) in older patients requiring dialysis is controversial. We reviewed our vascular access experience in patients ≥70 years of age (older group) compared with younger patients.Methods
We analyzed consecutive patients who underwent access surgery between 2013 and 2016. Primary success (PS) and primary patency (PP) data were analyzed between the older and younger groups before and after propensity score matching of the patients' characteristics and access composition. PS was defined as the achievement of access function that was amenable to two sessions of successful cannulation without early occlusion or maturation failure requiring revision. PP was defined as the time with uninterrupted patency without intervention.Results
A total of 594 consecutive accesses were created among 563 patients, of whom 119 were allocated into each group after propensity score matching. In the whole cohort, 193 accesses (32.5%) were performed in older patients. AVFs were performed in 130 (67.4%) older patients and 293 (73.1%) younger patients. Regarding AVFs, the PS rate (83.6% in the older group vs 94.3% in the younger group; P = .001) and the overall PP at 6 and 12 months (73.1% and 57.1%, respectively, in the older group vs 86.7% and 77.7%, respectively, in the younger group; P = .009) were lower in the older group than in the younger group. However, no differences were found in the PS and PP rates for arteriovenous grafts between groups. Regarding the AVF location, the PS rate for forearm AVFs was significantly lower in the older group than in the younger group (76% vs 93%; P < .001); however, the PS rate of the upper arm was not different between the groups (94% vs 97%; P = .425). In the patients with PS, the PP rate of AVFs was similar between the two groups. In the older group with forearm AVFs, the median diameter of the radial artery was larger in the patients with PS than in the patients without PS (2.20 mm with PS vs 2.00 mm without PS; P = .008). The propensity score matching results demonstrated similar trends for the whole cohort, with lower PS (P = .042) and PP rates (P = .023) for AVF in the older group.Conclusions
The outcomes after AVF were poorer in the older group than in the younger group, which was primarily due to unsatisfactory outcomes in patients with forearm AVFs. Thus, stricter criteria, especially regarding the radial artery diameter, should be applied for forearm AVFs in older patients, and additional research is necessary to delineate the risk factors for primary failure. 相似文献Methods: This is a retrospective analysis of discharge records from the National Inpatient Sample database for patients receiving allo-HSCT between 1 January 2009 and 31 December 2013. Allo-HSCT discharges with an aGVHD diagnosis were included in the aGVHD group and those without any graft-versus-host disease (GVHD) diagnosis comprised the non-GVHD group. Mortality, LOS and costs were compared between the two groups, as well as within subgroups, including age (<18 vs. ≥18 years) and survival status (alive vs. deceased) at discharge.
Results: Overall, mortality (16.2% vs. 5.3%; p?<?.01), median hospital LOS (42.0 vs. 26.0 days; p?<?.01) and median total costs ($173,144 vs. $98,982; p?<?.01) were significantly increased in patients with aGVHD versus those without GVHD during hospitalizations for allo-HSCT, irrespective of age group. Patients with aGVHD who were <18 years of age had a lower mortality rate but greater hospital LOS and total costs versus patients aged ≥18 years. Patients who died during allo-HSCT hospitalization had longer LOS and incurred greater costs than those who survived in both the aGVHD and non-GVHD groups.
Conclusion: Occurrence of aGVHD during allo-HSCT admissions resulted in a tripling of the mortality rate and a near doubling of hospital LOS and total costs. In addition, death during allo-HSCT hospitalizations was associated with greater healthcare utilization and costs. Effectively mitigating aGVHD may improve survival and substantially reduce hospital LOS and costs for allo-HSCT. 相似文献